ArticleProceedings of the National Academy of Sciences of the United States of America2023

Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound.

Claudia Janoschka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.